Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.35 |
| ▸ | BRS3 | P32247 | 5/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534713 | 0.80 | BRS3 (0.39) | AGTR1AGTR2BRS3 | |
| SCHEMBL9558428 | 0.79 | BRS3 (0.32) | AGTR1AGTR2BRS3PIN1 | |
| SCHEMBL9558706 | 0.78 | DHODH (0.30) | — | |
| SCHEMBL40 | 0.75 | AGTR1 (0.43) | AGTR1AGTR2 | |
| SCHEMBL7310628 | 0.73 | AGTR1 (0.36) | AGTR1AGTR2PIN1 | |
| SCHEMBL3841057 | 0.72 | AGTR1 (0.41) | AGTR1AGTR2 | |
| SCHEMBL7310241 | 0.71 | AGTR1 (0.36) | AGTR1AGTR2 | |
| SCHEMBL9251216 | 0.71 | AGTR1 (0.36) | AGTR1AGTR2 | |
| SCHEMBL10589833 | 0.70 | AGTR1 (0.37) | AGTR1AGTR2BRS3 | |
| SCHEMBL7175120 | 0.69 | AGTR1 (0.40) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004201-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-01-02 | — | — | US | disclosed |
| US-6025380-A | ANGIOTENSIN II RECEPTOR ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MACULAR DEGENERATION. | SMITHKLINE BEECHAM PLC (GB) | 2000-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004201-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR1 2/4885AGTR2 1/4885BRS3 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.